September 29, 2014
BELLSHILL, SCOTLAND -- LINK (www.linktech.co.uk), the specialist oligonucleotide reagent developer and manufacturer, has announced the appointment of Dr David Ricketts as its new Chief Executive Officer, taking over the position from current CEO, Dr John Bremner, on 20 October 2014. Of his appointment, Dr Ricketts said: “I'm delighted and very excited to join LINK as [...]
September 26, 2014
Capto S ImpAct is a strong cation exchanger for the intermediate and polishing steps when purifying MAbs and a wide range of other biomolecules. Part of the established Capto platform of high-performance chromatography media, Capto S ImpAct offers both high binding capacity and high resolution at high sample loads. The high-flow characteristics of the Capto [...]
September 26, 2014
Boston, MA - Ground-breaking advances in measurement technology and software control make the new DF-745SG GasMax from Servomex the most sensitive and flexible trace moisture analyzer available for Specialty Gas applications. Building on the success of the original DF-745SG, the GasMax is a sophisticated process analyzer optimized for measuring moisture in a specialty gas stream. [...]
Surface Enhanced Raman Spectroscopy Substrates from Ocean Optics
September 26, 2014
Dunedin, Florida, USA -– Ocean Optics has introduced a new substrate for Raman spectroscopy applications. Surface Enhanced Raman Spectroscopy (SERS) substrates are highly sensitive, stable and reliable, delivering precise trace-level Raman spectroscopy measurement in applications ranging from chemical and explosive agent detection, to authentication, contaminant screening and quality control in production environments and the laboratory. [...]
Stanford Researchers Use Single-Cell Mass Cytometry to Predict Recovery Time from Surgery
September 26, 2014
SOUTH SAN FRANCISCO, Calif.-- Researchers at Stanford University have demonstrated the ability to predict the recovery time of patients who underwent surgical trauma. Convalescence after surgery varies significantly from patient to patient—often with protracted recovery periods resulting in personal suffering as well as substantial societal and economic costs. Now, using the deep profiling capabilities of [...]
September 25, 2014
STEMCELL Technologies has received $949,500 in repayable assistance from the Western Innovation (WINN) Initiative for an exciting project to develop tools and assays for three-dimensional (3D) cell culture. Led by Dr. Steven Woodside, Director of Particle Chemistry and Engineering, and Dr. Eric Jervis, Principal Scientist, the project builds on STEMCELL Technologies’ extensive experience in developing [...]
GENAPSYS ANNOUNCES KEY HIRE TO SENIOR MANAGEMENT TEAM
September 25, 2014
Redwood City, California –– GenapSys Inc., the developer of the GENIUS DNA Sequencing System, today announced the appointment of Mark Pratt, Ph.D. as Vice President of Product Development. In his new role, Dr. Pratt will be a member of the GenapSys leadership team reporting to Hesaam Esfandyarpour, PhD, Founder & CEO. Most recently, Dr. Pratt [...]
BellBrook Labs and UW-Madison Team Awarded NCI Contract to Develop Next Generation Cancer Models
September 25, 2014
Madison, WI -- The National Cancer Institutes has awarded a $1.75M Small Business Innovative Research (SBIR) contract to BellBrook Labs for a collaborative effort with researchers at the University of Wisconsin-Madison to develop more realistic models for breast and ovarian cancer. The research will use imaging and microfabrication technology developed by the UW team to [...]
September 25, 2014
CARLSBAD, Calif. -- Thermo Fisher Scientific and pharmaceutical companies GlaxoSmithKline and Pfizer have entered into an agreement to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs. Thermo Fisher intends to submit this test for premarket approval to the Food and Drug [...]
Horizon Discovery Group plc Signs Master Services Agreement for Approximately $1.2 million
September 25, 2014
Cambridge, UK -- Horizon Discovery Group plc (LSE: HZD) (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announces that its business unit Horizon Diagnostics has signed a Master Services Agreement with a major global diagnostic development company and a US biopharmaceutical company to support the [...]
